Difference between revisions of "Duloxetine-maprotiline"
From Psychiatrienet
| Line 6: | Line 6: | ||
| start = | | start = | ||
No wash-out period is needed. | No wash-out period is needed. | ||
| − | * '''Day | + | * '''Day 8:''' start administration of maprotiline in a low dosage of 25 mg/day. |
| − | * '''Day | + | * '''Day 15:''' increase the dosage of maprotiline to 50 mg/day. |
| info = | | info = | ||
* Duloxetine slows the metabolism of maprotiline by CYP2D6. | * Duloxetine slows the metabolism of maprotiline by CYP2D6. | ||
}} | }} | ||
Revision as of 13:27, 18 January 2016
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from duloxetine to maprotiline.[1] [2]
Stop duloxetine - Before day 1: gradually reduce dosage of duloxetine to a maximum of 60 mg/ day, when this dosage is > 60 mg/day.
- Day 1: reduce dosage of duloxetine to a maximum of 30 mg/day.
- Day 8: stop administration of duloxetine.
Start maprotilineNo wash-out period is needed.
- Day 8: start administration of maprotiline in a low dosage of 25 mg/day.
- Day 15: increase the dosage of maprotiline to 50 mg/day.
More information- Duloxetine slows the metabolism of maprotiline by CYP2D6.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
